{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T03:54:06Z","timestamp":1775188446986,"version":"3.50.1"},"reference-count":48,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,28]]},"abstract":"Abstract<\/jats:title>Background:<\/jats:title>Antiplatelet therapy with clopidogrel is recommended to reduce cardiovascular events in patients with peripheral artery disease (PAD); however, clopidogrel efficacy has not been adequately studied in this patient population. Therefore, we aimed to determine the effects of cilostazol therapy on platelet reactivity among PAD patients on clopidogrel.<\/jats:p><\/jats:sec>Methods:<\/jats:title>We performed a cross-sectional pilot study of 46 Puerto Rican patients diagnosed with PAD. The cohort was divided based on use of clopidogrel and cilostazol (n=24) or clopidogrel alone (n=22). Platelet function was measuredex vivo<\/jats:italic>using the VerifyNow P2Y12 assay. Genomic DNA was extracted from peripheral blood samples using the QIAamp DNA Blood Midi Kit, which was subjected to candidate variant genotyping (CYP2C19<\/jats:italic>,ABCB1<\/jats:italic>,PON1<\/jats:italic>andP2RY12<\/jats:italic>) using TaqMan quantitative polymerase chain reaction assays. All analyses were performed using SAS version 9.4 (SAS Institute).<\/jats:p><\/jats:sec>Results:<\/jats:title>Among all enrolled patients, 18 (39%) had high on-treatment platelet reactivity (HTPR). The mean platelet reactivity was 207\u00b153 (range, 78\u2013325) with higher P2Y12 reaction units in the non-cilostazol group, 224\u00b145 vs. 191\u00b155 on the cilostazol group (p=0.03). No significant differences were observed in the clinical or genetic variables between the two groups. A multiple regression analysis determined that history of diabetes mellitus (p=0.03), use of cilostazol (p=0.03) and hematocrit (p=0.02) were independent predictors of platelet reactivity.<\/jats:p><\/jats:sec>Conclusions:<\/jats:title>In Puerto Rican PAD patients on clopidogrel therapy, history of diabetes mellitus, use of cilostazol and hematocrit are independent predictors of platelet reactivity. Adjunctive cilostazol therapy may enhance clopidogrel efficacy among PAD patients with HTPR.<\/jats:p><\/jats:sec>","DOI":"10.1515\/dmpt-2017-0032","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T10:01:01Z","timestamp":1517911261000},"page":"49-55","source":"Crossref","is-referenced-by-count":6,"title":["Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy"],"prefix":"10.1515","volume":"33","author":[{"given":"Dagmar F.","family":"Hernandez-Suarez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector","family":"N\u00fa\u00f1ez-Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel","family":"Lopez-Candales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M.","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario J.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Melin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karid","family":"Nieves-Borrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Rodriguez-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Duconge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","reference":[{"key":"ref41","first-page":"f5307","article-title":"Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison","volume":"347","year":"2013","journal-title":"Br Med J"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40291-013-0022-y","article-title":"Monitoring aspirin and clopidogrel response: testing controversies and recommendations","volume":"17","year":"2013","journal-title":"Mol Diagn Ther"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jacc.2006.03.038","article-title":"Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment","volume":"48","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","article-title":"Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease","volume":"64","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/cpt.401","article-title":"Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity","volume":"100","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/clpt.2011.132","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy","volume":"90","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/jth.13642","article-title":"The effect of correcting VerifyNow P2Y12 assay results for hematocrit in patients undergoing percutaneous coronary interventions","volume":"15","year":"2017","journal-title":"J Thromb Haemost"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jacc.2016.11.008","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"69","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"ref141","first-page":"610","article-title":"Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity","volume":"100","year":"2007","journal-title":"Am J Cardiol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.mrfmmm.2005.01.008","article-title":"Assessment of two flexible and compatible SNP genotyping platforms: TaqMan\u00ae SNP Genotyping Assays and the SNPlex\u2122 Genotyping System","volume":"573","year":"2005","journal-title":"Mutat Res"},{"key":"ref321","first-page":"f5307","article-title":"Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison","volume":"347","year":"2013","journal-title":"Br Med J"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"e0135692","DOI":"10.1371\/journal.pone.0135692","article-title":"Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: a systematic review and network meta-analysis","volume":"10","journal-title":"PLoS One"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jacc.2006.03.038","article-title":"Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment","volume":"48","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/jth.12376","article-title":"Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness","volume":"11","year":"2013","journal-title":"J Thromb Haemost"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1753944717718718","article-title":"Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics","volume":"11","year":"2017","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","year":"2009","journal-title":"N Engl J Med"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jcin.2010.12.010","article-title":"Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype","volume":"4","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1160\/TH08-03-0186","article-title":"Immature platelets in patients with acute coronary syndromes","volume":"101","year":"2009","journal-title":"Thromb Haemost"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejvs.2016.04.019","article-title":"High on-treatment platelet reactivity in peripheral arterial disease: a pilot study to find the optimal test and cut off values","volume":"52","year":"2016","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/1074248413495971","article-title":"Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis","volume":"18","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.jacc.2008.07.060","article-title":"Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality","volume":"52","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jacc.2016.11.008","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"69","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jacc.2008.12.025","article-title":"Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity","volume":"53","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jacc.2008.12.025","article-title":"Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity","volume":"53","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/bcp.12794","article-title":"The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes","volume":"81","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/cpt.401","article-title":"Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity","volume":"100","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jcin.2010.12.010","article-title":"Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype","volume":"4","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1753944717718718","article-title":"Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics","volume":"11","year":"2017","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","year":"2013","journal-title":"Lancet"},{"key":"ref421","first-page":"610","article-title":"Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity","volume":"100","year":"2007","journal-title":"Am J Cardiol"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1007\/s10903-014-0025-8","article-title":"High prevalence of diabetes and prediabetes and their coexistence with cardiovascular risk factors in a Hispanic community","volume":"17","year":"2015","journal-title":"J Immigr Minor Health"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/1074248413495971","article-title":"Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis","volume":"18","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/clpt.2011.132","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy","volume":"90","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/bcp.12794","article-title":"The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes","volume":"81","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","year":"2013","journal-title":"Lancet"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ijcard.2014.03.081","article-title":"Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading: the results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study","volume":"174","year":"2014","journal-title":"Int J Cardiol"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/jth.12376","article-title":"Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness","volume":"11","year":"2013","journal-title":"J Thromb Haemost"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.jacc.2008.07.060","article-title":"Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality","volume":"52","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1160\/TH08-03-0186","article-title":"Immature platelets in patients with acute coronary syndromes","volume":"101","year":"2009","journal-title":"Thromb Haemost"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","year":"2009","journal-title":"N Engl J Med"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejvs.2016.04.019","article-title":"High on-treatment platelet reactivity in peripheral arterial disease: a pilot study to find the optimal test and cut off values","volume":"52","year":"2016","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"e0135692","DOI":"10.1371\/journal.pone.0135692","article-title":"Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: a systematic review and network meta-analysis","volume":"10","journal-title":"PLoS One"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","article-title":"Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease","volume":"64","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1007\/s10903-014-0025-8","article-title":"High prevalence of diabetes and prediabetes and their coexistence with cardiovascular risk factors in a Hispanic community","volume":"17","year":"2015","journal-title":"J Immigr Minor Health"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ijcard.2014.03.081","article-title":"Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading: the results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study","volume":"174","year":"2014","journal-title":"Int J Cardiol"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40291-013-0022-y","article-title":"Monitoring aspirin and clopidogrel response: testing controversies and recommendations","volume":"17","year":"2013","journal-title":"Mol Diagn Ther"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/jth.13642","article-title":"The effect of correcting VerifyNow P2Y12 assay results for hematocrit in patients undergoing percutaneous coronary interventions","volume":"15","year":"2017","journal-title":"J Thromb Haemost"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.mrfmmm.2005.01.008","article-title":"Assessment of two flexible and compatible SNP genotyping platforms: TaqMan\u00ae SNP Genotyping Assays and the SNPlex\u2122 Genotyping System","volume":"573","year":"2005","journal-title":"Mutat Res"}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/dmdi.2018.33.issue-1\/dmpt-2017-0032\/dmpt-2017-0032.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2017-0032\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T21:51:43Z","timestamp":1619041903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2017-0032\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,28]]},"references-count":48,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1515\/dmpt-2017-0032","relation":{},"ISSN":["2363-8915","2363-8907"],"issn-type":[{"value":"2363-8915","type":"electronic"},{"value":"2363-8907","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3,28]]}}}